Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia
about
The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004Community acquired bacterial pneumoniaRespiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trialsBeta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysisPreventing and treating secondary bacterial infections with antiviral agentsStreptococcus pneumoniae Serotypes and Mortality in Adults and Adolescents in South Africa: Analysis of National Surveillance Data, 2003 - 2008.Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistanceMoxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.Severe pneumococcal pneumonia: impact of new quinolones on prognosis.Defining and predicting severe community-acquired pneumonia.Concurrent Infection with Hepatitis C Virus and Streptococcus pneumoniae.Epidemiology of pneumococcal disease in a national cohort of older adultsPrevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency MedicineMechanisms of action and clinical application of macrolides as immunomodulatory medications.Community-acquired pneumonia in elderly patients.Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin.Synergistic Effects of Bismuth Thiols and Various Antibiotics Against Pseudomonas aeruginosa BiofilmNew modalities in treating pneumococcal pneumonia.Recent advances in our understanding of Streptococcus pneumoniae infection.Critical care in AJRCCM 2004.Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfectionAntimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.Marked reduction in 30-day mortality among elderly patients with community-acquired pneumonia.Choosing the right combination therapy in severe community-acquired pneumoniaThe impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.Lung inflammatory pattern and antibiotic treatment in pneumoniaDefining severe pneumonia.Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types.Causes of non-adherence to therapeutic guidelines in severe community-acquired pneumoniaToll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenzaRespiratory Infections in the U.S. Military: Recent Experience and ControlImprovement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study.Pathogen- and host-directed anti-inflammatory activities of macrolide antibioticsGuidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults.Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.Does antibiotic selection impact patient outcome?Severe community-acquired pneumonia: approach to therapy.
P2860
Q21261529-B5E47637-0B7A-4EC5-A495-34DFC68BADDDQ22241379-CD4F5A5C-DA74-478E-B800-19D4E10031E5Q24655866-B2E0E750-5128-4910-AD3F-048BE3C4F706Q26747529-BAA5D54E-0A86-4286-AD5E-8B85B06C9756Q30401260-E3111B8B-CFC7-453F-BF47-18AA438E3F5EQ31004642-CF55ACAD-92AF-468C-A1AF-1FEBCB03934CQ33572569-73B0A7B6-944F-41B6-8F4D-D5AF1E29FA4BQ33749940-FBFE4B3B-804B-41D9-8EFF-442528AB4F60Q33801234-50C9F3E4-AC87-4745-92F5-692A9E53BBC7Q33846631-B274744C-C3EE-44CF-AE8F-5349A1D7B3E7Q33872274-7B271B4C-5072-4394-AD76-8B76524B4859Q33908082-E8C342CB-53E6-4387-B07D-998B8766E778Q33939120-B6832001-A6D3-4942-B7BF-7452309E18A7Q33974292-0D7CEA84-CD32-406F-9E5C-271BA0C470EBQ33983140-E50EEAED-29CB-427C-A14B-0A53834D8886Q34048462-87EAA2D3-4455-496F-83DA-6F9D5E0BEF9BQ34057612-076D93EF-0310-41CC-8F25-9937C401E926Q34068663-DCC17CEC-FA04-4FB1-9D58-B273EEBA241CQ34185386-DCFB3884-D84D-4D28-9910-BD80C4AA207FQ34201900-1F063725-9DE4-4DDC-9B50-F66EABB0201DQ34400957-87931C1D-473A-42A1-B786-CE506E7C9241Q34616215-F4718CA9-D0B7-40B4-94C1-71E4B7D70728Q34680540-D02F591E-0B9B-4186-910F-94199586911CQ34721918-E8758B4C-41FE-468E-AC38-4769939631FEQ34999131-3CECD29F-44F4-4AC0-83D2-667714F274BBQ34999299-B816A606-EEE6-4E0A-A2E9-6A5AAAF52905Q35083508-0B1663CB-8D9F-4225-835D-40D65CDF840AQ35184605-DE197FE6-CAAD-4137-AD2F-D45380236BF1Q35199208-9137060D-DD6E-40E9-8F94-4029ABBA0CB5Q35414598-BDBD1DEA-A041-4AE2-9980-27C60EE44EC2Q35557119-2055B04C-1561-402E-B7BE-F6C3D2F2736FQ35763405-15D57472-7066-48E3-A447-C0480A055758Q36061715-87745703-D707-4EBF-BDF6-E8628433ADFBQ36072425-24524543-911E-4FA9-AD8E-B7988FD577A4Q36281234-79B07E68-D462-41AC-8A69-3A4D7204117DQ36295507-7F092091-9749-4B9F-B155-6B46B75F617BQ36343776-5A6ABD80-AD31-4945-857B-77C3114E0DBDQ36634020-1F3EDED8-3009-4A5F-B798-BE3E04BE9D12Q36672883-98EB3096-DC8A-4440-AD7D-1F0AD883EABEQ36765778-B214DF08-43B7-4E9A-BB73-A92EB153FBEE
P2860
Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia
description
im Juni 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 07 June 2004
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2004
@uk
name
Combination Antibiotic Therapy ...... s with Pneumococcal Bacteremia
@en
Combination Antibiotic Therapy ...... s with Pneumococcal Bacteremia
@nl
type
label
Combination Antibiotic Therapy ...... s with Pneumococcal Bacteremia
@en
Combination Antibiotic Therapy ...... s with Pneumococcal Bacteremia
@nl
prefLabel
Combination Antibiotic Therapy ...... s with Pneumococcal Bacteremia
@en
Combination Antibiotic Therapy ...... s with Pneumococcal Bacteremia
@nl
P2093
P2860
P50
P1476
Combination antibiotic therapy ...... s with pneumococcal bacteremia
@en
P2093
Ake Ortqvist
Antoine Andremont
Arthur J Morris
Carlos M Luna
Charles Feldman
Christine C C Chiou
International Pneumococcal Study Group
Keith P Klugman
Larry M Baddour
M Bernadete F Chedid
P2860
P304
P356
10.1164/RCCM.200311-1578OC
P407
P577
2004-06-07T00:00:00Z